Anzeige
Mehr »
Samstag, 26.07.2025 - Börsentäglich über 12.000 News
Richtig investiert verwandelt der Goldpreis jeden Euro in glänzendes Vermögen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CWX9 | ISIN: US87583X1090 | Ticker-Symbol:
NASDAQ
25.07.25 | 21:59
6,810 US-Dollar
+0,89 % +0,060
1-Jahres-Chart
TANGO THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
TANGO THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur TANGO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiTango Therapeutics, Inc.: Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 20251
30.06.H.C. Wainwright bekräftigt Kaufempfehlung für Tango Therapeutics-Aktie14
30.06.H.C. Wainwright reiterates Buy rating on Tango Therapeutics stock1
27.06.Tango Therapeutics behandelt ersten Patienten in Krebsmedikamenten-Kombinationsstudie5
27.06.Tango Therapeutics doses first patient in cancer drug combo trial1
27.06.Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung ...186BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines...
► Artikel lesen
06.06.Tango Therapeutics, Inc. - 8-K, Current Report4
TANGO THERAPEUTICS Aktie jetzt für 0€ handeln
21.05.Tango Therapeutics starts trial for brain cancer drug3
21.05.Tango Therapeutics beginnt Studie für Gehirnkrebs-Medikament4
21.05.Tango Therapeutics, Inc.: Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors348BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines...
► Artikel lesen
12.05.Tango Therapeutics GAAP EPS of -$0.36 misses by $0.01, revenue of $5.39M misses by $1.34M2
12.05.Tango Therapeutics, Inc. - 10-Q, Quarterly Report2
12.05.Tango Therapeutics, Inc. - 8-K, Current Report1
12.05.Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights439- Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 - - Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 - - Cash position...
► Artikel lesen
09.05.Insights into Tango Therapeutics' Upcoming Earnings2
01.05.Tango Therapeutics, Inc.: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 20252
08.04.Tango Therapeutics cuts nearly one-fifth of staff3
25.03.Tango Therapeutics, Inc.: Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer Research (AACR) Annual Meeting 20252
27.02.Tango Therapeutics, Inc.: Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights299- TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer - - Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor...
► Artikel lesen
27.02.Tango Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1